ChemPartner PharmaTechLtd Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
ChemPartner PharmaTechLtd has a total shareholder equity of CN¥1.4B and total debt of CN¥136.0M, which brings its debt-to-equity ratio to 9.8%. Its total assets and total liabilities are CN¥2.2B and CN¥767.0M respectively.
Anahtar bilgiler
9.8%
Borç/özkaynak oranı
CN¥136.03m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | CN¥321.76m |
| Eşitlik | CN¥1.39b |
| Toplam yükümlülükler | CN¥766.98m |
| Toplam varlıklar | CN¥2.16b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
ChemPartner PharmaTech Co.,Ltd.'s (SZSE:300149) Price Is Right But Growth Is Lacking After Shares Rocket 51%
Sep 30
Improved Revenues Required Before ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) Stock's 29% Jump Looks Justified
Aug 04Chempartner Pharmatech Co., Ltd.'s (SZSE:300149) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Mar 08Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 300149's short term assets (CN¥624.0M) exceed its short term liabilities (CN¥347.2M).
Uzun Vadeli Yükümlülükler: 300149's short term assets (CN¥624.0M) exceed its long term liabilities (CN¥419.8M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 300149 has more cash than its total debt.
Borcun Azaltılması: 300149's debt to equity ratio has reduced from 34.4% to 9.8% over the past 5 years.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: Whilst unprofitable 300149 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Tahmini Nakit Akışı: 300149 is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 7.2% per year.